BRCA1 Ovarian Cancer: Mary's Patient Story

What happened, in summary

Three months after treatment for early-stage breast cancer, this nurse was preparing for a preventive hysterectomy because genetic testing had shown an inherited BRCA1 mutation. Preoperative testing instead revealed that she already had ovarian cancer. Surgery was scheduled within days of the diagnosis. The raw narrative focuses more clearly on the systemic treatment that followed: she became the first MD Anderson patient to receive a newly available outpatient form of intraperitoneal chemotherapy, delivered directly into the abdomen through a port. After that treatment, she became her doctor’s first patient to receive a newly available maintenance oral chemotherapy for late-stage ovarian cancer survivors.

She described the ovarian cancer treatment period as a long and difficult 2 years. Throughout treatment, she relied heavily on communication and support from her medical team and felt that new treatment options became available at important moments in her care.

The ovarian cancer diagnosis formed the second major part of a 4-year cancer journey that had begun with breast cancer. She remained alive and grateful for the care she received, while the source did not provide a more specific disease-status label after ovarian treatment.